Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
2.610
+0.130 (5.24%)
Jan 22, 2025, 10:53 AM EST - Market open
Salarius Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | - | - | - | 1.84 | 5.23 | 3.47 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | -64.84% | 51.03% | 77.57% | Upgrade
|
| Cost of Revenue | - | - | - | 8.55 | 6.91 | 4.02 | Upgrade
|
| Gross Profit | - | - | - | -6.71 | -1.68 | -0.55 | Upgrade
|
| Selling, General & Admin | 4.56 | 5.72 | 7.14 | 6.1 | 6.11 | 7.71 | Upgrade
|
| Research & Development | 0.65 | 7.17 | 15.84 | - | - | - | Upgrade
|
| Operating Expenses | 5.22 | 12.89 | 22.98 | 6.1 | 6.11 | 7.71 | Upgrade
|
| Operating Income | -5.22 | -12.89 | -22.98 | -12.81 | -7.79 | -8.27 | Upgrade
|
| Interest & Investment Income | 0.22 | 0.35 | 0.22 | - | - | 0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.01 | 0.04 | 0.43 | 1.31 | Upgrade
|
| EBT Excluding Unusual Items | -4.99 | -12.54 | -22.74 | -12.77 | -7.35 | -6.94 | Upgrade
|
| Impairment of Goodwill | - | - | -8.87 | - | - | - | Upgrade
|
| Pretax Income | -4.99 | -12.54 | -31.61 | -12.77 | -7.35 | -6.94 | Upgrade
|
| Net Income | -4.99 | -12.54 | -31.61 | -12.77 | -7.35 | -6.94 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.4 | - | Upgrade
|
| Net Income to Common | -4.99 | -12.54 | -31.61 | -12.77 | -7.75 | -6.94 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 103.91% | 53.66% | 28.40% | 165.53% | 376.61% | - | Upgrade
|
| EPS (Basic) | -6.89 | -30.74 | -119.02 | -61.73 | -99.48 | -424.42 | Upgrade
|
| EPS (Diluted) | -6.89 | -30.74 | -119.02 | -61.73 | -100.00 | -424.42 | Upgrade
|
| Free Cash Flow | -5.29 | -12.85 | -17.6 | -10.2 | -10.31 | -11.58 | Upgrade
|
| Free Cash Flow Per Share | -7.31 | -31.48 | -66.26 | -49.32 | -132.41 | -708.57 | Upgrade
|
| Gross Margin | - | - | - | - | -32.11% | -15.99% | Upgrade
|
| Operating Margin | - | - | - | -696.27% | -148.78% | -238.53% | Upgrade
|
| Profit Margin | - | - | - | -693.84% | -148.06% | -200.18% | Upgrade
|
| Free Cash Flow Margin | - | - | - | -554.29% | -197.08% | -334.20% | Upgrade
|
| EBITDA | -5.21 | -12.88 | -22.97 | -12.79 | -7.77 | -8.25 | Upgrade
|
| EBITDA Margin | - | - | - | - | -148.44% | -238.02% | Upgrade
|
| D&A For EBITDA | 0 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | Upgrade
|
| EBIT | -5.22 | -12.89 | -22.98 | -12.81 | -7.79 | -8.27 | Upgrade
|
| EBIT Margin | - | - | - | - | -148.78% | -238.53% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.